Share on StockTwits

Stifel Nicolaus began coverage on shares of LeMaitre Vascular (NASDAQ:LMAT) in a research note issued on Tuesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $11.00 price target on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 54.06% from the stock’s previous close.

The analysts wrote, “We are initiating coverage of LeMaitre Vascular, Inc. (LMAT) with a Buy rating and $11 target price, reflecting a 2.3x 2015 EV/sales multiple on our $75.7 million estimate. In our view, LeMaitre is a unique and under-appreciated, small-cap medical technology company, offering sustainable high single-digit, top-line growth and an improving profitability outlook. With an experienced, highly disciplined, and dedicated management team (insiders own 34%), we see LeMaitre shares offering a relatively predictable total-return profile, suitable for long-term investors.”

LMAT has been the subject of a number of other recent research reports. Analysts at Stifel initiated coverage on shares of LeMaitre Vascular in a research note on Tuesday. They set a “buy” rating and a $11.00 price target on the stock. Separately, analysts at Brean Capital initiated coverage on shares of LeMaitre Vascular in a research note on Monday, May 19th. They set a “buy” rating and a $11.00 price target on the stock. Finally, analysts at ING Group initiated coverage on shares of LeMaitre Vascular in a research note on Monday, May 19th. They set a “buy” rating and a $11.00 price target on the stock. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $10.54.

Shares of LeMaitre Vascular (NASDAQ:LMAT) traded up 9.80% during mid-day trading on Tuesday, hitting $7.8399. 19,160 shares of the company’s stock traded hands. LeMaitre Vascular has a 52 week low of $6.38 and a 52 week high of $8.96. The stock’s 50-day moving average is $7.6 and its 200-day moving average is $7.90. The company has a market cap of $122.6 million and a P/E ratio of 51.37.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.01 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.02 by $0.01. Analysts expect that LeMaitre Vascular will post $0.23 EPS for the current fiscal year.

LeMaitre Vascular, Inc (NASDAQ:LMAT) is a global provider of medical devices and implants for the treatment of peripheral vascular disease.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.